NASDAQ:KURA Kura Oncology (KURA) Stock Forecast, Price & News $13.20 -0.30 (-2.22%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$13.14▼$13.6850-Day Range$9.62▼$13.9952-Week Range$9.49▼$19.93Volume621,132 shsAverage Volume646,178 shsMarket Capitalization$903.41 millionP/E RatioN/ADividend YieldN/APrice Target$29.71 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Kura Oncology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside125.1% Upside$29.71 Price TargetShort InterestBearish12.42% of Float Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.98Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.33) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector593rd out of 983 stocksPharmaceutical Preparations Industry295th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.71, Kura Oncology has a forecasted upside of 125.1% from its current price of $13.20.Amount of Analyst CoverageKura Oncology has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.42% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Kura Oncology has recently decreased by 0.38%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kura Oncology is -0.76. Previous Next 2.2 News and Social Media Coverage News SentimentKura Oncology has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kura Oncology this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Kura Oncology is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to grow in the coming year, from ($2.33) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kura Oncology (NASDAQ:KURA) StockKura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.Read More Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address KURA Stock News HeadlinesMay 30, 2023 | finance.yahoo.comKura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) CongressMay 29, 2023 | markets.businessinsider.comKura Oncology (KURA) Gets a Buy from Stifel NicolausJune 2, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 19, 2023 | msn.comUnusual Call Option Trade in Kura Oncology (KURA) Worth $317.50KMay 19, 2023 | americanbankingnews.comKura Oncology (NASDAQ:KURA) Earns Buy Rating from Analysts at BTIG ResearchMay 18, 2023 | seekingalpha.comKura Oncology (KURA) Investor Presentation - SlideshowMay 18, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Kura Oncology (NASDAQ:KURA)May 18, 2023 | americanbankingnews.comKura Oncology (NASDAQ:KURA) Shares Gap Down to $12.66June 2, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 17, 2023 | msn.comBTIG Initiates Coverage of Kura Oncology (KURA) with Buy RecommendationMay 17, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Their Buy Rating for Kura Oncology (KURA)May 16, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Kura Oncology, Inc. (NASDAQ:KURA) Raised by AnalystMay 16, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Kura Oncology, Inc. Cut by Analyst (NASDAQ:KURA)May 16, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Kura Oncology, Inc. (NASDAQ:KURA) Issued By HC WainwrightMay 14, 2023 | americanbankingnews.comStifel Nicolaus Lowers Kura Oncology (NASDAQ:KURA) Price Target to $24.00May 13, 2023 | finance.yahoo.comKura Oncology, Inc. (NASDAQ:KURA) Q1 2023 Earnings Call TranscriptMay 13, 2023 | americanbankingnews.comKura Oncology, Inc. (NASDAQ:KURA) to Post FY2025 Earnings of $4.86 Per Share, Brookline Capital Management ForecastsMay 13, 2023 | americanbankingnews.comBrokerages Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $29.60May 12, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on Kura Oncology (KURA)May 11, 2023 | msn.comCredit Suisse Reiterates Kura Oncology (KURA) Outperform RecommendationMay 11, 2023 | msn.comHC Wainwright & Co. Reiterates Kura Oncology (KURA) Buy RecommendationMay 11, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Zai Lab (ZLAB)May 11, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Kura Oncology (KURA)May 11, 2023 | finance.yahoo.comQ1 2023 Kura Oncology Inc Earnings CallMay 10, 2023 | msn.comKura Oncology: Q1 Earnings InsightsMay 10, 2023 | finance.yahoo.comKura Oncology Reports First Quarter 2023 Financial ResultsMay 10, 2023 | finance.yahoo.comKura Oncology Reports First Quarter 2023 Financial ResultsSee More Headlines KURA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KURA Company Calendar Last Earnings5/10/2023Today6/02/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KURA CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees121Year FoundedN/APrice Target and Rating Average Stock Price Forecast$29.71 High Stock Price Forecast$40.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+124.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.64% Return on Assets-30.52% Debt Debt-to-Equity Ratio0.02 Current Ratio21.65 Quick Ratio21.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.77 per share Price / Book2.29Miscellaneous Outstanding Shares68,440,000Free Float64,743,000Market Cap$906.15 million OptionableOptionable Beta0.86 Key ExecutivesTroy E. WilsonChairman, President, CEO & Chief Financial OfficerKathleen FordChief Operating OfficerStephen DaleChief Medical OfficerMollie LeoniSenior Vice President-Clinical DevelopmentThomas DoyleChief Accounting Officer & Senior VP-FinanceKey CompetitorsInnovivaNASDAQ:INVAMorphoSysNASDAQ:MORuniQureNASDAQ:QURE23andMeNASDAQ:MEDay One BiopharmaceuticalsNASDAQ:DAWNView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,614 shares on 5/26/2023Ownership: 0.018%New York State Common Retirement FundSold 16,083 shares on 5/18/2023Ownership: 0.043%Geode Capital Management LLCBought 57,110 shares on 5/16/2023Ownership: 1.880%Sphera Funds Management LTD.Bought 45,000 shares on 5/16/2023Ownership: 0.881%Squarepoint Ops LLCSold 39,101 shares on 5/16/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions KURA Stock - Frequently Asked Questions Should I buy or sell Kura Oncology stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KURA shares. View KURA analyst ratings or view top-rated stocks. What is Kura Oncology's stock price forecast for 2023? 7 brokerages have issued 12-month price objectives for Kura Oncology's stock. Their KURA share price forecasts range from $22.00 to $40.00. On average, they predict the company's stock price to reach $29.71 in the next twelve months. This suggests a possible upside of 125.1% from the stock's current price. View analysts price targets for KURA or view top-rated stocks among Wall Street analysts. How have KURA shares performed in 2023? Kura Oncology's stock was trading at $12.41 on January 1st, 2023. Since then, KURA stock has increased by 6.4% and is now trading at $13.20. View the best growth stocks for 2023 here. When is Kura Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our KURA earnings forecast. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) issued its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.04. What ETFs hold Kura Oncology's stock? ETFs with the largest weight of Kura Oncology (NASDAQ:KURA) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD). What is Kura Oncology's stock symbol? Kura Oncology trades on the NASDAQ under the ticker symbol "KURA." Who are Kura Oncology's major shareholders? Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.84%), Suvretta Capital Management LLC (9.60%), BlackRock Inc. (7.85%), State Street Corp (5.61%), Dimensional Fund Advisors LP (2.68%) and Geode Capital Management LLC (1.88%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Marc Grasso, Thomas James Doyle and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kura Oncology's stock price today? One share of KURA stock can currently be purchased for approximately $13.20. How much money does Kura Oncology make? Kura Oncology (NASDAQ:KURA) has a market capitalization of $903.41 million. The company earns $-135,840,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. How many employees does Kura Oncology have? The company employs 121 workers across the globe. How can I contact Kura Oncology? Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for the company is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com. This page (NASDAQ:KURA) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.